This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutCurrent Treatment LandscapeMechanism Of Action (MOA)DosingDosingRecommended dosing scheduleEfficacy & Safety ProfileEfficacy & SafetyAcute Clinical EfficacyPrevention Clinical EfficacySafety and Tolerability ProfileSupporting ResourcesSupport & ResourcesMaterialsVideosOnline Learning

Click here for Vydura® (rimegepant) Prescribing Information for Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page.

Recommended Dosing ScheduleDosing for VYDURA in adults:For acute treatment of migraine with or without aura*

The recommended dose is 75 mg VYDURA, as needed. The maximum dose per day of VYDURA is 75 mg1

For preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month*

The recommended dose is 75 mg VYDURA every other day. The maximum dose per day of VYDURA is 75 mg1

Another dose of VYDURA within 48 hours should be avoided when it is concomitantly administered with moderate inhibitors of CYP3A4 or strong inhibitors of P-gp. For more information, please refer to the SmPC

Patient advice for VYDURA

Patients should be advised to used dry hands when opening the blister and referred to the package leaflet for complete instructions1

Mechanism of ActionLearn about the MOA for Vydura, a CGRP receptor antagonist Mechanism of ActionLoadingAcute Clinical EfficacyDiscover VYDURA’s efficacy in treating acute migraines Acute Clinical EfficacyLoading

Please refer to the package leaflet or SPC for complete instructions.

The oral lyophilisates shown in the icons are for illustrative purposes only and do not represent the actual size. Following administration of rimegepant under fed conditions with a high-fat or low-fat meal, Tmax was delayed by 1 to 1.5 hours.1
 

No more than one VYDURA oral lyophilisate should be taken in a 24 hour period. Note that another dose of VYDURA within 48 hours should be avoided when it is concomitantly administered with moderate inhibitors of CYP3A4 or strong inhibitors of P-gp. For more information, please refer to the SmPC

Coadministration of medications
  • VYDURA can be co-administered with oral contraceptives2
  • In clinical trials, participants were allowed to use rimegepant alongside rescue medication (i.e. NSAIDs, paracetamol and/ or an antiemetic), the use of triptans was not allowed within 48 hours of initial treatment1
  • Another dose of VYDURA within 48 hours should be avoided  when it is concomitantly administered with moderate  inhibitors of CYP3A4 (e.g. fluconazole) or strong inhibitors of P-gp (e.g. cyclosporine, verapamil, quinidine)1

CYP3A4, cytochrome P450 3A4; NSAID; non-steroidal anti-inflammatory drug; P-gp, P-glycoprotein; Tmax, time to peak drug concentration
*VYDURA 75 mg oral lyophilisate contains gelatin, mannitol, mint flavour and sucralose1
Consider recommending VYDURA as one of the targeted therapies for the treatment of acute migraine with or without aura in adults or the preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month1,3
Explore morePrevious page

Learn about the MOA for Vydura, a CGRP receptor antagonist

Mechanism of Action
Next page

Discover VYDURA’s efficacy in treating acute migraines

Acute Efficacy Endpoints
Register for PfizerProSign up to recieve tailored content specific to your interest Register here
References:
  1. Vydura (rimegepant) Summary of Product Characteristics for Great Britain; Vydura (rimegepant) Summary of Product Characteristics for Northern Ireland
  2. Szkutnik-Fiedler D. Pharmaceutics 2020; 12:1180
  3. Vydura (rimegepant) Package Leaflet: Information for the Patient
PP-NNT-GBR-2250. October 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​